TherapeuticsMD, Inc 8-K, filed Jun 3, 2022
TherapeuticsMD, Inc. (TXMD)
About this 8-K
TherapeuticsMD, Inc filed this 8-K on June 3, 2022, reporting on events of May 27, 2022.
Items reported
- Item 1.01: Entered into a material agreement
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
|
|
|
(Exact Name of Registrant as Specified in its Charter) |
|
|
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer |
|
|
|
(Address of Principal Executive Office) (Zip Code) |
Registrant’s telephone number, including area code:
|
Not Applicable |
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 1.01 |
Entry into a Material Definitive Agreement. |
Effective May 27, 2022, the Board of Directors of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), adopted and approved an amendment to the Bylaws of the Company, as previously amended (the “Bylaw Amendment”), to render the provisions of Nevada’s acquisition of controlling interest statutes (NRS 78.378 through 78.3793, inclusive) not applicable to the Agreement and Plan of Merger, dated as of May 27, 2022 (the “Merger Agreement”), among the Company, Athene Parent, Inc. and Athene Merger Sub, Inc. (“Merger Sub”), the acquisition of any shares of the Company’s capital stock thereunder or the consummation of any transactions contemplated thereby, including, without limitation, the cash tender offer to be commenced by Merger Sub to acquire all of the issued and outstanding shares of the common stock, par value $0.001 per share, of the Company and the merger of Merger Sub with and into the Company, with the Company as the surviving entity.
The foregoing description of the Bylaw Amendment is only a summary and is qualified in its entirety by reference to the complete text of the Bylaw Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d)Exhibits
|
Exhibit Index |
||
|
|
||
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
|
|
3.1 |
|
Second Amendment to Bylaws of the Company, adopted May 27, 2022. |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: June 3, 2022 |
|
THERAPEUTICSMD, INC.
|
|
|
|
|
|
|
|
/s/ Michael C. Donegan |
|
|
|
Michael C. Donegan |
|
|
|
Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance |
Exhibit 3.1
SECOND AMENDMENT TO BYLAWS
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), desires to amend its Bylaws.
Article XIII – Inapplicability of NRS 78.378 through 78.3793
Article XIII of the Bylaws shall be added as follows:
ARTICLE XIII – (INAPPLICABILITY OF NRS 78.378 THROUGH 78.3793)
Notwithstanding any other provision of these Bylaws to the contrary, the provisions of NRS 78.378 through 78.3793, inclusive, shall not be applicable to the Agreement and Plan of Merger Agreement, dated as of May 27, 2022 (the “Merger Agreement”), by and among the Corporation, Athene Parent, Inc., a Nevada corporation, and Athene Merger Sub, Inc., a Nevada corporation, to the acquisition of any shares of the Corporation’s capital stock thereunder or the consummation of any transactions contemplated thereby, including, without limitation, the Offer (as defined therein), and the Merger (as defined therein), or by the other documents, instruments and arrangements contemplated by the Merger Agreement.
* * * * *
Except as expressly amended or modified by this Second Amendment to Bylaws, all of the terms and conditions of the Bylaws shall remain unchanged and in full force and effect.
IN WITNESS WHEREOF, the undersigned officer of the Company hereby certifies that the foregoing Second Amendment to the Bylaws was duly adopted by the board of directors of the Company effective as of the 27th day of May, 2022.
|
|
|
THERAPEUTICSMD, INC.
|
|
|
|
|
|
|
|
/s/ Marlan D. Walker |
|
|
|
By: Marlan D. Walker |
|
|
|
Its: Secretary |